Bbva Compass Bancshares Inc. Purchases 69 Shares of DexCom, Inc. (DXCM)
Bbva Compass Bancshares Inc. boosted its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 1.9% during the second quarter, Holdings Channel reports. The fund owned 3,670 shares of the medical device company’s stock after buying an additional 69 shares during the period. Bbva Compass Bancshares Inc.’s holdings in DexCom were worth $268,000 at the end of the most recent reporting period.
Other hedge funds have also recently added to or reduced their stakes in the company. Livforsakringsbolaget Skandia Omsesidigt purchased a new stake in DexCom during the first quarter valued at $136,000. Shell Asset Management Co. increased its position in shares of DexCom by 10.7% in the first quarter. Shell Asset Management Co. now owns 23,887 shares of the medical device company’s stock worth $2,024,000 after buying an additional 2,314 shares in the last quarter. Sit Investment Associates Inc. increased its position in shares of DexCom by 159.8% in the first quarter. Sit Investment Associates Inc. now owns 23,900 shares of the medical device company’s stock worth $2,025,000 after buying an additional 14,700 shares in the last quarter. Independent Portfolio Consultants Inc. increased its position in shares of DexCom by 97.6% in the first quarter. Independent Portfolio Consultants Inc. now owns 2,490 shares of the medical device company’s stock worth $211,000 after buying an additional 1,230 shares in the last quarter. Finally, Mn Services Vermogensbeheer B.V. increased its position in shares of DexCom by 3.8% in the first quarter. Mn Services Vermogensbeheer B.V. now owns 2,254 shares of the medical device company’s stock worth $179,000 after buying an additional 83 shares in the last quarter.
Shares of DexCom, Inc. (DXCM) opened at 71.54 on Thursday. The stock’s market cap is $6.19 billion. The company has a 50-day moving average price of $71.63 and a 200-day moving average price of $75.29. DexCom, Inc. has a 12 month low of $57.68 and a 12 month high of $96.38.
DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Tuesday, August 1st. The medical device company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.07. The company had revenue of $170.60 million for the quarter, compared to analyst estimates of $166.54 million. DexCom had a negative return on equity of 27.90% and a negative net margin of 10.27%. The firm’s revenue was up 24.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.24) earnings per share. On average, analysts expect that DexCom, Inc. will post ($0.77) EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Bbva Compass Bancshares Inc. Purchases 69 Shares of DexCom, Inc. (DXCM)” was published by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be accessed at https://www.watchlistnews.com/bbva-compass-bancshares-inc-purchases-69-shares-of-dexcom-inc-dxcm/1468143.html.
A number of brokerages have commented on DXCM. BidaskClub upgraded shares of DexCom from a “strong sell” rating to a “sell” rating in a report on Wednesday. BMO Capital Markets reiterated an “outperform” rating and issued a $90.00 target price (down from $105.00) on shares of DexCom in a report on Tuesday. Zacks Investment Research downgraded shares of DexCom from a “hold” rating to a “sell” rating in a report on Friday, August 4th. TheStreet upgraded shares of DexCom from a “d” rating to a “c-” rating in a report on Wednesday, August 2nd. Finally, Stephens reiterated an “overweight” rating and issued a $83.00 target price (down from $95.00) on shares of DexCom in a report on Wednesday, August 2nd. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and fifteen have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $87.00.
In other DexCom news, EVP Steven Robert Pacelli sold 1,450 shares of DexCom stock in a transaction that occurred on Monday, July 24th. The stock was sold at an average price of $69.47, for a total value of $100,731.50. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Richard Doubleday sold 3,182 shares of DexCom stock in a transaction that occurred on Tuesday, May 23rd. The shares were sold at an average price of $68.29, for a total value of $217,298.78. Following the completion of the transaction, the executive vice president now owns 72,395 shares in the company, valued at $4,943,854.55. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 33,131 shares of company stock worth $2,318,443. 1.70% of the stock is currently owned by corporate insiders.
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.
Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM).
Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.